Marie Jeansson

Please have a look at www.jeanssonlab.com for more information about our work!

I am a associate professor in vascular biology with a long-standing interest in how blood vessels in the kidney contribute to both health and disease. Over the years, I have combined methods ranging from electron microscopy and in vivo models of glomerular injury to modern single-cell and spatial transcriptomics. These approaches allow me to map the heterogeneity of endothelial cells in health and in conditions such as diabetic nephropathy. I am particularly interested in how molecular pathways such as Tie2/angiopoietin signalling and endothelial–podocyte cross-talk can be targeted to preserve capillary integrity, slow chronic kidney disease progression, and ultimately protect patients from kidney failure.

My translational ambition is to move beyond understanding mechanisms toward developing new treatments. I am the co-founder and CEO of Sang Biotech AB, a Swedish biotech company that builds on my laboratory’s discoveries to create therapies for kidney and cardiovascular diseases. At Sang Biotech, we aim to translate insights about endothelial injury and repair into drug candidates that strengthen the vasculature and restore function. My work stands at the interface of basic vascular biology and clinical nephrology. By bridging these fields, I hope to redefine kidney disease as a disorder of the entire vascular niche and to contribute to therapies that address the root causes of organ damage, not only its symptoms.